Reduction of Insulin Resistance With Effective Clearance of Hepatitis C Infection: Results From the HALT-C Trial

• Published in: Clinical gastroenterology and hepatology Vol. 8; no. 5; pp. 458 - 462
• Main Authors: Delgado–Borrego, Aymin, Jordan, Sergio H, Negre, Betania, Healey, David, Lin, Wenyu, Kamegaya, Yoshitaka, Christofi, Marielle, Ludwig, David A, Lok, Anna S.F, Chung, Raymond T
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2010
• Subjects: Adiponectin; Adult; Aged; Cirrhosis; Female; Gastroenterology and Hepatology; HALT-C; Hepatitis C - complications; Hepatitis C - drug therapy; HOMA; Humans; Insulin Resistance; Interferon; Interferon-alpha - therapeutic use; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols - therapeutic use; Recombinant Proteins; Ribavirin - therapeutic use; RNA, Viral - blood; Viral Load; HALT-C; body mass index; IR; TMA; Hepatitis C Antiviral Long-Term Treatment against Cirrhosis; AN; HOMA2-IR; transcription-mediated amplification; Adiponectin; Cirrhosis; TNF-α; tumor necrosis factor–α; HOMA; Interferon; insulin resistance; homeostasis model assessment; BMI

Background & Aims Hepatitis C virus (HCV) infection is associated with an increased prevalence of diabetes and insulin resistance (IR); whether this is a causal relationship has not been established. Methods We performed a longitudinal study within the lead-in phase of the Hepatitis C Antiviral...